A Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC 716051) for Primary and Recurrent Operable Malignant GIST Expressing the KIT Receptor Tyrosine Kinase (CD117).
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 07 Jul 2009 Actual end date (1 Jan 2009) as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.